Fennec Pharmaceuticals Inc.
FENCHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeFennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. With a market capitalization of $343.5M, it sits in small-cap territory. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
Market Cap
$343.5M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
9.63
EPS (TTM)
$-0.29
EPS (Fwd)
$1.03
ROE
-52.7%
ROA
-5.9%
Cash
$40.2M
Total Debt
$0
Free CF
-$2.4M
52W Change
21.8%
Annual Financials
Cash vs Debt
Fennec Pharmaceuticals Inc. reports $40.2M in cash and $0 in total debt. Free cash flow is running at -$2.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -52.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.5M (2022) to $44.6M (2025), reflecting a 2808% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fennec Pharmaceuticals Inc. and its sector.